// App-Quantinova.ai

: Study of AUTO3, the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22, Followed By Anti-PD1 Consolidation in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Alexander Study

Researchers

Presenter

  • Kirit Ardeshna

Principal Investigators

  • Maria A V Marzolini

  • Wendy Osborne

  • Muhammad Al-Hajj

  • Simon Thomas

  • Jim Faulkner

  • Martin Pule

  • Vijay G R Peddareddigari

  • Nushmia Z Khokhar

Medical Centers

  • University College London Hospitals NHS Trust, London, United Kingdom

  • Department of Urology, King's College Hospital NHS Foundation Trust, London, United Kingdom

  • Newcastle upon Tyne Hospitals Trust, Newcastle upon Tyne, United Kingdom

  • Autolus Ltd, London, GBR

  • Dolon Ltd, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Lymphomas

Biomarkers

  • Coxsackie Virus And Adenovirus Receptor

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved